Co-development

Disruptive Pharma collaborates with external partners on formulation- and product development projects where Formulite is applied to address key challenges in oral drug development. These tailored B2B projects range from early feasibility assessments to advanced formulation development and scale-up, integrated into the partner’s existing development and lifecycle management programs.

Typical formulation challenges addressed include:

• Improving bioavailability for poorly soluble or dissolution-limited compounds
• Enabling high drug loading and flexible dosing
• Simplifying formulation design and manufacturing
• Reducing polymer burden and solvent-intensive processing

Projects are structured with clear technical scope, timelines, and decision points, enabling efficient evaluation of Formulite and informed development decisions.

Product candidates

Disruptive Pharma develops differentiated, added-value oral drug product candidates, primarily based on established active pharmaceutical ingredients (APIs).

The pipeline spans preclinical and clinical programs, with an initial focus on oncology with expansion into additional therapeutic areas. Selected candidates are available for out-licensing, co-development, or strategic partnerships, depending on partner objectives and development strategy.

By applying Formulite, Disruptive Pharma enhances key product attributes, including bioavailability, dosing regimen, tolerability, and stability, creating differentiated oral drug candidates for partnering.

Intellectual property framework

Disruptive Pharma holds exclusive worldwide rights to manufacture and use the Formulite technology in pharmaceutical applications. The intellectual property portfolio includes granted and pending patents covering drug loading and formulation principles involving mesoporous magnesium carbonate (MMC).

In addition, reformulated drug products can be protected through formulation-specific patents, supporting the use of Formulite in lifecycle management and product differentiation strategies.

Formulite is made available to development partners across two use cases:

• Formulation of drugs in development, including novel chemical entities (NCE)
• Reformulation of established active pharmaceutical ingredients (API)

In both cases, Disruptive Pharma works closely with partners to define appropriate IP strategies and maximize the value of the underlying innovation, enabling the translation of formulation advances into novel, protectable, and commercially viable oral drug products.

Lifecycle management

For many drugs side effects may limit the usage despite a highly efficacious mechanism of action, often driven by low bioavailability and consequently high API dosing. Formulite is ideally suited to address the root cause of the side effects and improve patient tolerability of these drugs. With an established regulatory pathway and exclusivity protection through a formulation patent, Formulite is ideally suited as a lifecycle management initiative. Formulite  offers an attractive combination of excellent amorphous API stability, improved bioavailability, scalable manufacturing and stronger patent protection for the product.

Formulite is expected to be regulated as an excipient, with reformulated products following applicable regulatory guidelines.